Behavioral alterations associated with levetiracetam in pediatric epilepsy

Cortes, Camila; Manterola, Carla

doi:10.1016/j.yebeh.2020.107472

Cited by 5 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Adverse behavioral effects in children associated with LEV treatment affect 15-38.5% of patients with NI and more in patients with ID [ 16 , 17 , 18 , 19 , 20 , 21 ]. The rate of adverse reactions in this study was 14% and 10% in groups of NI and ID, respectively.…”

Section: Discussionmentioning

confidence: 99%

Comparative Efficacy of Levetiracetam for Epilepsy in School-Aged Children with Intellectual Disability and Normal Intelligence

Moon

Han

2021

Brain Sciences

View full text Add to dashboard Cite

Choosing optimal anti-seizure medication (ASM) is very important in pediatric patients with epilepsy who attend school, especially children with an intellectual disability (ID). Levetiracetam (LEV) has proven to be an effective, safe, generally well-tolerated, broad-spectrum ASM in children. In the context of increasing use of LEV in school-aged children with epilepsy and ID, we evaluate relevant clinical data, including efficacy, safety, and tolerability in children with epilepsy and an intellectual disability (ID) or normal intelligence (NI). We performed a retrospective chart review of children and included 298 pediatric patients with epilepsy who were treated with LEV with NI (147) and ID (151). After 6 months, 96% of NI and 83% of ID subjects had a seizure reduction rate greater than 50% (p = 0.031). The tolerability of LEV was generally good, with 75% retention rates at 2 years in both groups and only minor side effects (under 15%). The retention rates of patients with NI and ID were 76% and 74%, respectively (p = 0.597). Thus, LEV showed considerable efficacy with minimal side effects and high retention rates and is an easily maintained and safe treatment option for pediatric epilepsy with ID. However, better-designed research studies are needed to clearly elucidate the efficacy and safety of LEV in children with epilepsy and ID.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparative Efficacy of Levetiracetam for Epilepsy in School-Aged Children with Intellectual Disability and Normal Intelligence

Moon

Han

2021

Brain Sciences

View full text Add to dashboard Cite

show abstract

Safety and efficacy of levetiracetam and carbamazepine monotherapy in the management of pediatric focal epilepsy: a randomized clinical trial

Montazerlotfelahi,

Haj Mohamad Ebrahim Ketabforoush,

Tavakol

et al. 2024

Naunyn-Schmiedeberg's Arch Pharmacol

View full text Add to dashboard Cite

Background: Due to the limited number of studies in children with focal epilepsy and the importance of choosing the most suitable drug to control seizures in children, the administration of the most effective medication with the most negligible side effects is vital.Objectives: This study aimed to evaluate the effectiveness and side effects of Carbamazepine vs.Levetiracetam monotherapy in children with focal seizures. Design: A monocentric, randomized, controlled, double-blind, parallel-group clinical trial Setting: This study was approved by the Iranian Registry of clinical trials (registration number:

show abstract

Anti-epileptic medications

Maroney

Marković

2021

Side Effects of Drugs Annual

View full text Add to dashboard Cite

Behavioral alterations associated with levetiracetam in pediatric epilepsy

Cited by 5 publications

References 19 publications

Comparative Efficacy of Levetiracetam for Epilepsy in School-Aged Children with Intellectual Disability and Normal Intelligence

Comparative Efficacy of Levetiracetam for Epilepsy in School-Aged Children with Intellectual Disability and Normal Intelligence

Safety and efficacy of levetiracetam and carbamazepine monotherapy in the management of pediatric focal epilepsy: a randomized clinical trial

Anti-epileptic medications

Contact Info

Product

Resources

About